Virgil Thompson - Mallinckrodt Plc Independent Director
| MNKDelisted Stock | USD 0.34 0.00 0.00% |
Director
Mr. Virgil D. Thompson, J.D., is an Independent Director of the Company. Mr. Thompson served as a director of Questcor Pharmaceuticals, Inc. from 1996 and most recently served as Chairman of its Board until Questcor was acquired by us in August 2014. From July 2009 to July 2015, Mr. Thompson served as Chief Executive Officer and director of Spinnaker Biosciences, Inc., a privately held ophthalmic drug delivery company, and now serves as Chairman of the Board. Mr. Thompson is also the Chairman of the Board of Aradigm Corporationrationration, a public company, and a director of GenZ Corporationrationration, a private company. Mr. Thompson served as the President, Chief Executive Officer and as a director of Angstrom Pharmaceuticals, Inc. from 2002 until 2007. From 2000 until 2002, Mr. Thompson was President, Chief Executive Officer and a director of Chimeric Therapies, Inc. From 1999 until 2000, Mr. Thompson was President, Chief Operating Officer and, from 1994, a director of BioTechnology General Corporationrationration, a pharmaceutical company since 2014.
| Age | 75 |
| Tenure | 10 years |
| Phone | 353 1 696 0000 |
| Web | https://www.mallinckrodt.com |
Virgil Thompson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Virgil Thompson against Mallinckrodt Plc stock is an integral part of due diligence when investing in Mallinckrodt Plc. Virgil Thompson insider activity provides valuable insight into whether Mallinckrodt Plc is net buyers or sellers over its current business cycle. Note, Mallinckrodt Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Mallinckrodt Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Virgil Thompson over six months ago Processa Pharmaceuticals exotic insider transaction detected |
Mallinckrodt Plc Management Efficiency
Mallinckrodt Plc's management efficiency ratios could be used to measure how well Mallinckrodt Plc manages its routine affairs as well as how well it operates its assets and liabilities.The company has 3.07 B in debt with debt to equity (D/E) ratio of 1.44, which is OK given its current industry classification. Mallinckrodt Plc has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Mallinckrodt Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Mallinckrodt Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mallinckrodt Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mallinckrodt to invest in growth at high rates of return. When we think about Mallinckrodt Plc's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Emmanuel Caeymaex | Journey Medical Corp | 46 | |
| Paul Ingram | Aurora Cannabis | N/A | |
| David Cohen | Journey Medical Corp | 53 | |
| Murray Garnick | Cronos Group | 58 | |
| Toai Nguyen | Aurora Cannabis | 58 | |
| Ryan Roebuck | Cronos Group | 31 | |
| Bruce Gates | Cronos Group | 56 | |
| Jason Dyck | Aurora Cannabis | N/A | |
| Bronwen Evans | Cronos Group | 48 | |
| Jijing Niu | Aurora Cannabis | N/A | |
| Peter Pizzo | Alimera Sciences | 50 | |
| Charles Rifici | Aurora Cannabis | N/A | |
| Jake Nunn | Journey Medical Corp | 47 | |
| James Largent | Alimera Sciences | 67 | |
| Kathleen Sebelius | Journey Medical Corp | 69 | |
| Peter Stringham | Canopy Growth Corp | N/A | |
| John FisherStamp | Aurora Cannabis | N/A | |
| Norma Beauchamp | Aurora Cannabis | 59 | |
| Murray Goldman | Canopy Growth Corp | N/A | |
| Diane Jang | Aurora Cannabis | N/A | |
| Jason Adler | Cronos Group | 46 | |
Management Performance
| Return On Equity | -1.11 | |||
| Return On Asset | -0.0029 |
Mallinckrodt Plc Leadership Team
Elected by the shareholders, the Mallinckrodt Plc's board of directors comprises two types of representatives: Mallinckrodt Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mallinckrodt. The board's role is to monitor Mallinckrodt Plc's management team and ensure that shareholders' interests are well served. Mallinckrodt Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mallinckrodt Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Phillips, Executive Vice President and Chief Strategy Officer | ||
| Steven Romano, Executive Vice President and Chief Scientific Officer | ||
| Mark Casey, Executive Vice President and Chief Legal Officer | ||
| JoAnn Reed, Independent Director | ||
| Virgil Thompson, Independent Director | ||
| Lisa French, Ex Officer | ||
| Stephen Welch, Ex Generics | ||
| Henriette Nielsen, Ex Officer | ||
| Steven MD, Ex Officer | ||
| Diane Gulyas, Independent Director | ||
| Joseph Zaccagnino, Independent Director | ||
| Paul Carter, Independent Director | ||
| David Carlucci, Independent Director | ||
| CPA CPA, Global Officer | ||
| George Kegler, CFO, Executive Vice President | ||
| Frank Scholz, Executive Vice President and Chief Operations and Digital Innovation Officer | ||
| David Norton, Independent Director | ||
| Hugh ONeill, Executive Vice President and President, Autoimmune and Rare Diseases | ||
| Martin Carroll, Independent Director | ||
| Steve Romano, Senior Vice President Chief Scientific Officer | ||
| Sigurdur Olafsson, Pres CEO | ||
| Mark Trudeau, CEO and President Director and Member of Portfolio Committee | ||
| Kneeland Youngblood, Independent Director | ||
| Bryan Reasons, Chief Financial Officer, Executive Vice President | ||
| J Carroll, Independent Director | ||
| Meredith Fischer, Senior Vice President - Communications and Public Affairs | ||
| Kassie Harrold, Ex Officer | ||
| Jason Goodson, Exec Devel | ||
| Terrance Carlson, Senior Vice President and General Counsel - Interim | ||
| Ian Watkins, Chief Human Resource Officer, Executive Vice President | ||
| Dagmar RosaBjorkeson, Chief Strategy and Corporate Development Officer | ||
| Melvin Booth, Independent Chairman of the Board | ||
| Raymond Furey, Senior Vice President Chief Compliance Officer | ||
| Angus Russell, Independent Non-Executive Chairman of the Board | ||
| Ronald Lloyd, Executive Vice President and President - Hospital Therapies | ||
| Karen Sheehy, Chief Compliance Officer | ||
| Matthew Harbaugh, CFO and Sr. VP | ||
| MichaelBryant Hicks, General Counsel | ||
| Carlos Paya, Independent Director | ||
| Anne Whitaker, Independent Director | ||
| Mark Tyndall, Chief VP |
Mallinckrodt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mallinckrodt Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.11 | |||
| Return On Asset | -0.0029 | |||
| Profit Margin | (0.83) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 2.62 B | |||
| Shares Outstanding | 13.29 M | |||
| Shares Owned By Insiders | 10.09 % | |||
| Shares Owned By Institutions | 96.64 % | |||
| Number Of Shares Shorted | 1.79 M | |||
| Price To Earning | 1.09 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mallinckrodt Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mallinckrodt Plc's short interest history, or implied volatility extrapolated from Mallinckrodt Plc options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Mallinckrodt Stock
If you are still planning to invest in Mallinckrodt Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mallinckrodt Plc's history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |